Cholestatic and Autoimmune Liver Diseases SIG: Bile Acid Signaling and Cholestatic Liver Diseases
Recorded On: 11/08/2019
Recent approval of the synthetic FXR agonist obeticholic acid for primary biliary cholangitis treatment shows that targeting nuclear receptors in treating liver diseases, particularly cholestatic and autoimmune conditions, has therapeutic potential.
Saul J. Karpen
Keith D. Lindor